Inlexzo System
NDC 57894-225
Product Information
Inlexzo (gemcitabine intravesical) is a NDA-approved product labeled by Janssen Biotech, Inc. This medication is typically used as a nucleic acid synthesis inhibitors [moa]. It is supplied as a system for intravesical administration. This product entry covers the primary NDC 57894-225 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 57894-225?
What are the uses of this product?
What are Active Ingredients of this product?
- GEMCITABINE 225 mg/1 - A deoxycytidine antimetabolite used as an antineoplastic agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GEMCITABINE (UNII: B76N6SBZ8R)
- GEMCITABINE (UNII: B76N6SBZ8R) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
- POVIDONE K30 (UNII: U725QWY32X)
- UREA (UNII: 8W8T17847W)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- POLYETHYLENE OXIDE 600000 (UNII: 2126FD486L)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2723386 - gemcitabine 225 MG Intravesical System
- RxCUI: 2723386 - gemcitabine 225 MG Drug Implant
- RxCUI: 2723391 - inlexzo 225 MG Intravesical System
- RxCUI: 2723391 - gemcitabine 225 MG Drug Implant [Inlexzo]
- RxCUI: 2723391 - Inlexzo 225 MG Intravesical System
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.